Astellas pauses Audentes' gene therapy program again after 'abnormal' liver tests in yet another setback
Audentes’ troubled the gene therapy program for a rare and devastating muscle wasting disease isn’t yet out of the woods.
The Astellas subsidiary has once …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
